No wonder my IBS got better when I was on Metformin. I may try to start "Metformin Synergy" from Empower Pharmacy with Leucine and low dose sildenafil (yes, Viagra) to see if I do not lose muscle pump or get tired like I did with Metformin monotherapy 500 mg twice per day. I could use losing a few of my quarantine pounds also. These are not human studies but...
Anti-inflammatory mechanism of metformin and its effects in intestinal inflammation and colitis-associated colon cancer - PubMed
These results indicate that metformin suppresses NF-κB activation in intestinal epithelial cells and ameliorates murine colitis and colitis-associated tumorigenesis in mice, suggesting that metformin could be a potential therapeutic agent for the treatment of inflammatory bowel disease.pubmed.ncbi.nlm.nih.gov
Metformin Ameliorates Inflammatory Bowel Disease by Suppression of the STAT3 Signaling Pathway and Regulation of the between Th17/Treg Balance
Objective Metformin is used to treat type 2 diabetes. We sought to determine whether metformin reduces inflammation, by regulating p-signal transducer and activator of transcription 3 (STAT3) expression and T-helper 17 (Th17) cell proliferation, in a mouse model of inflammatory bowel disease...journals.plos.org
Love Affair With Metformin: Still Strong, or Time to Move On?
.... "at $4 a month," it's hard to argue with the economics, she noted.
Newer drugs that have shown benefit in cardiovascular outcomes trials include the SGLT-2 inhibitors empagliflozin (Jardiance, Boehringer Ingelheim) in EMPA-REG OUTCOME and canagliflozin (Invokana, Johnson & Johnson) in CANVAS, and the GLP-1 agonists liraglutide (Victoza, Novo Nordisk) in LEADER and semaglutide (Ozempic, Novo Nordisk) in SUSTAIN-6.
But these studies were mainly conducted in patients with high-risk type 2 diabetes who had a long duration of disease and already had cardiovascular disease (CVD) or a number of risk factors for it.
"So these data do not directly translate to 87% of our population," requiring first-line therapy for type 2 diabetes, Aroda argued.
She also pointed to safety, acknowledging, "We all know the potential for gastrointestinal disturbances with metformin and B12 deficiency," but this pales in comparison to the numerous safety warnings issued for newer drugs over the past few years, she said."
..."metformin does not address many of the core pathophysiologies of type 2 diabetes, she argued, and secondly, "you do not improve metabolic parameters as well as other [drugs] can." Although metformin lowers HbA1c, it is fairly neutral when it comes to any benefits on weight, blood pressure, and lipids, for example."
Source
AIDS Research and Human Retroviruses- Ahead of PrintFull Access
Effects of Brief Adjunctive Metformin Therapy in Virologically Suppressed HIV-Infected Adults on Polyfunctional HIV-Specific CD8 T Cell Responses to PD-L1 Blockade
Glen M. Chew,
Ana Joy P. Padua,
Dominic C. Chow,
Scott A. Souza,
Danielle M. Clements,
Michael J. Corley,
Alina P.S. Pang,
Marissa M. Alejandria,
Mariana Gerschenson,
Cecilia M. Shikuma, and
Lishomwa C. Ndhlovu
Published Online:5 Nov 2020my.access — University of Toronto Libraries Portal
Abstract
Targeting inhibitory immune checkpoint receptor pathways has shown remarkable success in improving anticancer T cell responses for the elimination of tumors. Such immunotherapeutic strategies are being pursued for HIV remission. Metformin has shown favorable clinical outcomes in enhancing the efficacy of programmed cell death-1 (PD-1) blockade and restoring antitumor T cell immunity. Furthermore, monocytes are known to be a strong predictor of progression-free survival in response to anti-PD-1 immunotherapy. In a single-arm clinical trial, we evaluated the immunological effects over an 8-week course of metformin therapy in seven euglycemic, virally suppressed HIV-infected participants on combination antiretroviral therapy (cART). We assessed changes in peripheral HIV-Gag-specific T cell responses to immune checkpoint blockade (ICB) with anti-PD-L1 and anti-T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) monoclonal antibodies (mAbs) and changes in CD8 T cell and monocyte subsets using flow cytometry. Study participants were all male, 71% (5/7) Caucasian, with a median age of 61 years, CD4 count of 739 cells/μL, and plasma HIV RNA of <50 copies/mL on stable cART for >1 year. Ex vivo polyfunctional HIV-Gag-specific CD8 T cell responses to anti-PD-L1 mAb significantly improved (p < .05) over the 8-week course of metformin therapy. Moreover, frequencies of both intermediate (CD14+CD16+; r = 0.89, p = .01) and nonclassical (CD14lowCD16+; r = 0.92, p = .01) monocytes at entry were predictive of the magnitude of the anti-HIV CD8 T cell responses to PD-L1 blockade. Collectively, these findings highlight that 8-week course of metformin increases the polyfunctionality of CD8 T cells and that baseline monocyte subset frequencies may be a potential determinant of PD-L1 blockade efficacy. These data provide valuable information for HIV remission trials that utilize ICB strategies to enhance anti-HIV CD8 T cell immunity.
More on Metformin and HIV:
Metformin Synergy Capsules
Choose Empower Pharmacy for compounded Metformin Synergy Capsules. The leading accredited 503A and FDA-registered 503B compounding pharmacy.www.empowerpharmacy.com
Metformin Weight Loss Combo: Effect of Leucine plus Metformin and Sildenafil Combination
Objective: Leucine was previously demonstrated to allosterically activate mammalian sirtuin 1 and synergize with other sirtuin 1/AMP-activated protein kinase/nitric oxide pathway activators to modulate energy metabolism. The objective of this study was to evaluate the effects of a triple...www.excelmale.com
I thought you would find that interesting.Thanks for sharing!
Let's see what this study shows:
TAME - Targeting Aging with Metformin - American Federation for Aging Research
The Targeting Aging with Metformin (TAME) Trial is a series of nationwide clinical trials to uncover what metformin means for older populations living longer and healthier lives.www.afar.org
A new study explores anti-aging properties of metformin
Research has found that metformin targets the chemicals produced by age-related senescent cells—normal cells that stop dividing and produce toxic substances damaging to the cells around them, said James Kirkland, director of the Robert and Arlene Kogod Center on Aging at the Mayo Clinic in...www.excelmale.com
There has been a study shown according to Dr. Stanfield (recent) that metformin does not decrease risk of heart disease or cancer. It does do a great job of preventing type 2 diabetes though!I thought you would find that interesting.
In terms of awaiting further data and outcomes with TAME, I agree. I'm looking forward to reviewing data beyond what's easily measurable.
He's referring to the paper I posted above.There has been a study shown according to Dr. Stanfield (recent) that metformin does not decrease risk of heart disease or cancer. It does do a great job of preventing type 2 diabetes though!
okay !He's referring to the paper I posted above.
The authors of the paper state that their study was not fully controlled, we're still awaiting further research as Nelson mentioned.
Sorry to hear you stopped. I actually welcome the GI disturbances as a sign the medication is working. If we eat clean it isn't so bad.I'm off metformin mainly because my GI didn't tolerate it well. gas/shits. I also remember reading it reduces IGF considerably, and lastly I remember some problematic cancer stuff with long term. I actually do think it permanently improved my insulin sensitivity though--even after I stopped it.
Metformin gives my wife horrible stomach cramps and diarrhea.